Format

Send to

Choose Destination
J Biomed Sci. 2017 Apr 4;24(1):26. doi: 10.1186/s12929-017-0329-9.

Cancer immunotherapies targeting the PD-1 signaling pathway.

Author information

1
Department of Molecular Biology, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu-shi, Fukuoka, 807-8555, Japan.
2
Department of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
3
Department of Immunology and Genomic Medicine, Graduate School of Medicine, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan.
4
Department of Immunology and Genomic Medicine, Graduate School of Medicine, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan. honjo@mfour.med.kyoto-u.ac.jp.

Abstract

Immunotherapy has recently emerged as the fourth pillar of cancer treatment, joining surgery, radiation, and chemotherapy. While early immunotherapies focused on accelerating T-cell activity, current immune-checkpoint inhibitors take the brakes off the anti-tumor immune responses. Successful clinical trials with PD-1 monoclonal antibodies and other immune-checkpoint inhibitors have opened new avenues in cancer immunology. However, the failure of a large subset of cancer patients to respond to these new immunotherapies has led to intensified research on combination therapies and predictive biomarkers. Here we summarize the development of PD-1-blockade immunotherapy and current issues in its clinical use.

KEYWORDS:

Cancer immunotherapy; Immune checkpoint; PD-1; PD-L1

PMID:
28376884
PMCID:
PMC5381059
DOI:
10.1186/s12929-017-0329-9
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center